Understanding Patient Variability

Unlike statins, antihypertensives, anticoagulants, and other critical therapies, antiplatelet medications are given with the assumption that all patients respond equally, but they do not.

Up to One out of every Three patients may not be responding adequately to their antiplatelet therapy.¹
Numerous factors may contribute to inadequate response, including²:

• Genetic differences (e.g. CYP2C19)
FDA and the makers of Plavix warned that the effectiveness of Plavix^®
may be reduced in some patients.

• Concomitant medications (e.g. proton pump inhibitors)

• Pre-existing health conditions
(e.g. diabetes, impaired renal function, obesity)

• Non-compliance

Patients who are not responding adequately to their antiplatelet therapy may be at
significantly higher risk of heart attack, stent thrombosis and death.^5-8

A new medication, Effient^®, is now available to help combat the risk of heart attack, but may not be the right treatment for all patients.

In minutes, the VerifyNow^®System, proven in over 200
peer-reviewed publications that demonstrate its clinical utility and analytical performance,9 provides you with an easy and rapid solution to assess how your patient’s platelets are responding to antiplatelet medications such as aspirin, Plavix^®, Effient^®, Ticlid^®, ReoPro^®and Intergrilin^®.

Click here to learn more about the  Solution.

References